Relief Therapeutics Holding AG (RLF) - Total Assets
Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) holds total assets worth CHF47.99 Million CHF (≈ $60.67 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Relief Therapeutics Holding AG for net asset value and shareholders' equity analysis.
Relief Therapeutics Holding AG - Total Assets Trend (2006–2024)
This chart illustrates how Relief Therapeutics Holding AG's total assets have evolved over time, based on quarterly financial data.
Relief Therapeutics Holding AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Relief Therapeutics Holding AG's total assets of CHF47.99 Million consist of 37.0% current assets and 63.0% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 28.3% |
| Accounts Receivable | CHF2.03 Million | 3.8% |
| Inventory | CHF1.04 Million | 2.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF30.73 Million | 57.7% |
| Goodwill | CHF295.00K | 0.6% |
Asset Composition Trend (2006–2024)
This chart illustrates how Relief Therapeutics Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RLF stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Relief Therapeutics Holding AG's current assets represent 37.0% of total assets in 2024, an increase from 21.2% in 2006.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2024, up from 1.5% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 1.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 57.7% of total assets.
Relief Therapeutics Holding AG Competitors by Total Assets
Key competitors of Relief Therapeutics Holding AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Relief Therapeutics Holding AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.05 | 3.09 | 0.53 |
| Quick Ratio | 3.80 | 3.01 | 0.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF11.44 Million | CHF9.95 Million | CHF-2.70 Million |
Relief Therapeutics Holding AG - Advanced Valuation Insights
This section examines the relationship between Relief Therapeutics Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -30.3% |
| Total Assets | CHF53.22 Million |
| Market Capitalization | $36.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Relief Therapeutics Holding AG's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Relief Therapeutics Holding AG's assets decreased by 30.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Relief Therapeutics Holding AG (2006–2024)
The table below shows the annual total assets of Relief Therapeutics Holding AG from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF53.22 Million ≈ $67.29 Million |
-30.33% |
| 2023-12-31 | CHF76.39 Million ≈ $96.58 Million |
-59.54% |
| 2022-12-31 | CHF188.80 Million ≈ $238.69 Million |
-24.97% |
| 2021-12-31 | CHF251.62 Million ≈ $318.11 Million |
+222.40% |
| 2020-12-31 | CHF78.05 Million ≈ $98.67 Million |
+292.92% |
| 2019-12-31 | CHF19.86 Million ≈ $25.11 Million |
-44.17% |
| 2018-12-31 | CHF35.58 Million ≈ $44.98 Million |
+14.87% |
| 2017-12-31 | CHF30.97 Million ≈ $39.16 Million |
-1.44% |
| 2016-12-31 | CHF31.42 Million ≈ $39.73 Million |
+4.28% |
| 2015-12-31 | CHF30.13 Million ≈ $38.10 Million |
-27.60% |
| 2014-12-31 | CHF41.62 Million ≈ $52.62 Million |
-9.48% |
| 2013-12-31 | CHF45.98 Million ≈ $58.13 Million |
+3471.27% |
| 2012-12-31 | CHF1.29 Million ≈ $1.63 Million |
-60.71% |
| 2011-12-31 | CHF3.28 Million ≈ $4.14 Million |
-94.38% |
| 2010-12-31 | CHF58.30 Million ≈ $73.71 Million |
-10.60% |
| 2009-12-31 | CHF65.22 Million ≈ $82.45 Million |
-14.93% |
| 2008-12-31 | CHF76.66 Million ≈ $96.92 Million |
-3.12% |
| 2007-12-31 | CHF79.13 Million ≈ $100.04 Million |
+3.08% |
| 2006-12-31 | CHF76.76 Million ≈ $97.05 Million |
-- |
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more